HK63991A - Stable injectable pharmaceutical formulation for 1,4-dihydroxy-5,8-bis((2-(hydroxyethylamino)-ethyl)amino)anthraquinone, dihydrochloride - Google Patents

Stable injectable pharmaceutical formulation for 1,4-dihydroxy-5,8-bis((2-(hydroxyethylamino)-ethyl)amino)anthraquinone, dihydrochloride Download PDF

Info

Publication number
HK63991A
HK63991A HK639/91A HK63991A HK63991A HK 63991 A HK63991 A HK 63991A HK 639/91 A HK639/91 A HK 639/91A HK 63991 A HK63991 A HK 63991A HK 63991 A HK63991 A HK 63991A
Authority
HK
Hong Kong
Prior art keywords
hydroxyethylamino
anthraquinone
dihydroxy
dihydrochloride
bis
Prior art date
Application number
HK639/91A
Other languages
German (de)
English (en)
Inventor
Pradeep V. Niphadkar
Narendra R. Desai
Paul N. Jones
Kieran G. Mooney
Original Assignee
Wyeth Holdings Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Holdings Corporation filed Critical Wyeth Holdings Corporation
Publication of HK63991A publication Critical patent/HK63991A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Claims (2)

1. Une formulation pharmaceutique comprenant de 1 à 5 mg par ml de formulation de dichlorhydrate de 1,4-dihydroxy-5,8-bis[2-(2-hydroxyéthy!amino)éthy)amino]anthraquinone dans une solution isotonique à un pH de 2,0 à 3,5, contenant du métabilsulfite de sodium à une concentration de 0,01 à 0,10%, du EDTA disodique à une concentration de 0,01 à 0,11 % et de la glycine à une concentration de 0,05 à 0,20%.
2. Une formulation selon la revendication 1, selon laquelle la concentration du dichlorhydrate de 1,4-dihydroxy-5,8-bis[2-(2-hydroxyéthylamino)éthylamino]anthraquinone est de 2 mg/ml et les concentrations de métabisulfite de sodium, de EDTA disodique et de glycine sont de 0,05%, de 0,10% et de 0,10% respectivement.
HK639/91A 1986-03-07 1991-08-15 Stable injectable pharmaceutical formulation for 1,4-dihydroxy-5,8-bis((2-(hydroxyethylamino)-ethyl)amino)anthraquinone, dihydrochloride HK63991A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83724386A 1986-03-07 1986-03-07

Publications (1)

Publication Number Publication Date
HK63991A true HK63991A (en) 1991-08-23

Family

ID=25273922

Family Applications (1)

Application Number Title Priority Date Filing Date
HK639/91A HK63991A (en) 1986-03-07 1991-08-15 Stable injectable pharmaceutical formulation for 1,4-dihydroxy-5,8-bis((2-(hydroxyethylamino)-ethyl)amino)anthraquinone, dihydrochloride

Country Status (21)

Country Link
EP (1) EP0236822B1 (fr)
JP (1) JPH0717500B2 (fr)
KR (1) KR900002030B1 (fr)
AT (1) ATE59290T1 (fr)
AU (1) AU593330B2 (fr)
CA (1) CA1283607C (fr)
DE (1) DE3766984D1 (fr)
DK (1) DK166754B1 (fr)
ES (1) ES2033247T3 (fr)
FI (1) FI84977C (fr)
GR (1) GR3001503T3 (fr)
HK (1) HK63991A (fr)
HU (1) HU199286B (fr)
IE (1) IE60025B1 (fr)
IL (1) IL81681A (fr)
NO (1) NO173635C (fr)
NZ (1) NZ219454A (fr)
PH (1) PH22808A (fr)
PT (1) PT84398B (fr)
SG (1) SG45292G (fr)
ZA (1) ZA871652B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE188870T1 (de) * 1994-10-04 2000-02-15 Lohmann Rudolf Lomapharm Lösungen von anthrachinonen zur parenteralen applikation
DE19818802A1 (de) * 1998-04-27 1999-10-28 Dresden Arzneimittel Stabile Mitoxantron-Lösungen
TW200526268A (en) * 2003-12-17 2005-08-16 Takeda Pharmaceutical Injectable composition
EP2649993B1 (fr) * 2010-12-09 2017-04-05 Maruishi Pharmaceutical Co., Ltd. Stabilisant d'acétaminophène
CN114601791B (zh) * 2020-12-08 2023-09-19 成都倍特药业股份有限公司 一种盐酸米托蒽醌液体制剂及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3230143A (en) * 1965-05-14 1966-01-18 Merck & Co Inc Antihypertensive injection methods using acid addition salts of alkyl esters of alpha-methyl-3, 4-dihy-droxyphenylalanine
US4223022A (en) * 1978-01-16 1980-09-16 Schering Corporation Stabilized aminoglycoside antibiotic formulations
US4328213A (en) * 1979-11-28 1982-05-04 Schering Corporation Stable injectable labetalol formulation
EP0154117B1 (fr) * 1984-02-27 1989-12-27 American Cyanamid Company Utilisation des anthrachinones 1,4 bi-substitueés pour la fabrication des medicaments immunosuppresives

Also Published As

Publication number Publication date
FI84977C (fi) 1992-02-25
NO173635C (no) 1994-01-12
ATE59290T1 (de) 1991-01-15
PH22808A (en) 1988-12-27
PT84398B (pt) 1989-10-04
KR870008581A (ko) 1987-10-19
SG45292G (en) 1992-06-12
IL81681A0 (en) 1987-09-16
NZ219454A (en) 1989-04-26
NO870950D0 (no) 1987-03-06
JPS62265220A (ja) 1987-11-18
IL81681A (en) 1991-01-31
FI870994A0 (fi) 1987-03-06
IE870569L (en) 1987-09-07
DK116687D0 (da) 1987-03-06
EP0236822A2 (fr) 1987-09-16
KR900002030B1 (ko) 1990-03-31
DK116687A (da) 1987-09-08
DK166754B1 (da) 1993-07-12
EP0236822B1 (fr) 1990-12-27
DE3766984D1 (de) 1991-02-07
AU593330B2 (en) 1990-02-08
FI870994L (fi) 1987-09-08
NO870950L (no) 1987-09-08
HU199286B (en) 1990-02-28
IE60025B1 (en) 1994-05-18
EP0236822A3 (en) 1989-01-11
HUT47020A (en) 1989-01-30
JPH0717500B2 (ja) 1995-03-01
FI84977B (fi) 1991-11-15
PT84398A (en) 1987-04-01
NO173635B (no) 1993-10-04
ES2033247T3 (es) 1993-03-16
CA1283607C (fr) 1991-04-30
GR3001503T3 (en) 1992-11-23
ZA871652B (en) 1987-08-28
AU6977387A (en) 1987-09-10

Similar Documents

Publication Publication Date Title
FI114444B (fi) Menetelmä aktiiviainetta sisältävän transdermaalisen valmisteen valmistamiseksi
US3070499A (en) Parenteral aqueous solutions of fat soluble vitamins
ZA200200215B (en) Moxifloxacin formulation containing common salt.
HU9400430D0 (en) New pyrazine derivatives, their preparation and pharmaceutical compositions containing them
JPH0399012A (ja) 経口投与可能なｎ―アセチル―システイン含有製剤
US4883805A (en) Stable, Injectable solutions of vinca dimer salts
EP0236822B1 (fr) Formulation pharmaceutique injectable stable à base du dichlorhydrate de la 1,4-dihydroxy-5,8-bis((2-(hydroxyéthylamino)-éthyl)amino)anthraquinone
US4784855A (en) Pharmaceutical compositions and suppository
CA2270004C (fr) Solutions de mitoxantrone stables
TW372193B (en) Novel pharmaceutical composition for the preparation of a stable powder containing an association of acetylsalicylic acid and metoclopramide as the active ingredient
US3526698A (en) Stabilization of levo-3-(3,4-dihydroxyphenyl)-2-methylalanine with sodium bisulfite and sorbitol
KR100514009B1 (ko) 1,2,4-벤조트리아진옥사이드제제
JPH05139955A (ja) 安定な点眼剤
CA2534259A1 (fr) Preparation ayant une concentration elevee en glycyrrhizine
EP0236280B1 (fr) Formulations pharmaceutiques injectables de principes actifs à activité anesthésique générale
JPH09169642A (ja) テトラヒドロゾリン含有液剤
JPH069430A (ja) 安定なリゾチーム配合点眼剤
EP1569663B1 (fr) Compositions a base d'ifosfamide pour l'administration parenterale et leur procede de preparation
JP2000256186A (ja) 咽頭疾患用組成物
JPS59210040A (ja) ヒノキチオ−ルの安定化法
MXPA00010224A (en) Stable mitoxantron solutions
JP2023093952A (ja) 水性組成物
JPS5780317A (en) Preparation of pharmaceutical composition for injection
CA2487153A1 (fr) Nouvelle formulation permettant d'administrer de la crobenetine par voie parenterale
ZA200601268B (en) Formulations of anthraquinone derivatives

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20060220